| 4.25 0.04 (0.95%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.23 | 1-year : | 5.6 |
| Resists | First : | 4.47 | Second : | 4.8 |
| Pivot price | 4.52  |
|||
| Supports | First : | 3.96 | Second : | 3.29 |
| MAs | MA(5) : | 4.38 |
MA(20) : | 4.53 |
| MA(100) : | 4.68 |
MA(250) : | 5.03 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 28.6 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 16.25 | Low : | 3.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RADX ] has closed above bottom band by 1.2%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.29 - 4.32 | 4.32 - 4.34 |
| Low: | 3.98 - 4.01 | 4.01 - 4.04 |
| Close: | 4.2 - 4.25 | 4.25 - 4.29 |
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Thu, 04 Jun 2026
RADX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Thu, 04 Jun 2026
Radiopharm Theranostics stock initiated with buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Thu, 04 Jun 2026
This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Sahm
Thu, 23 Apr 2026
Brain metastases imaging trial completes enrollment; 2 more cancer studies start - Stock Titan
Tue, 24 Mar 2026
Brain metastases scan matches MRI in 90% of Radiopharm trial patients - Stock Titan
Wed, 11 Mar 2026
Radiopharm: 'Hold' As Theranostics Pipeline Has Several 2026 Milestones (NASDAQ:RADX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 2,370 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 47 (K) |
| Shares Short P.Month | 40 (K) |
| EPS | -3.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | -286.2 % |
| Operating Margin | -423.8 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -92.1 % |
| Qtrly Rev. Growth | 154.5 % |
| Gross Profit (p.s.) | -2.82 |
| Sales Per Share | 2.06 |
| EBITDA (p.s.) | -4.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -37 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.31 |
| Price to Sales | 2.05 |
| Price to Cash Flow | -0.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|